A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Recruiting

Phase 2

EmpasiprubartA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Sponsor:

argenx

Code:

NCT06284954

Conditions

Dermatomyositis

Myositis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Empasiprubart IV

Placebo IV

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by argenx on 2025-05-05.